| |
|
Executive
Briefing
Challenges in the antibacterial
market
Moving out of survival mode
The past year's tough economic environment has brought
a sharp decline in available venture capital. Challenges are obvious and
abundant, yet growing medical needs provide market pressure and significant
commercial opportunities await. The rapidly changing drug development
landscape requires new tools, market approaches, viewpoints, partnerships,
and clinical practices. Be prepared as investment resumes along with the
improving worldwide economic climate!
This Executive Briefing will open your eyes to emerging opportunities
and provide insights to help you move out of survival mode early in the
coming anti-infective business cycle!
We will address challenges and opportunities for partnership as well
as highlight key opportunities in the current market and forward 10 years.
We will take an in-depth look at non-dilutive financing vehicles, changing
business models and competitive landscape, rapidly escalating medical
demands, diagnostics co-development, adaptions in physician prescription
habits, the cleared up regulatory environment, and international aspects.
| Program |
- Current market overview - facts and figures for the antibacterial
market, existing drugs and therapies
- Medical need - resistance driven
- Competitive landscape - 10 years and beyond
- Emerging trends - innovative approaches, personalized medicine,
comparative effectiveness, public campaigns
- Development & market challenges - regulatory demands and
recent experience, differentiation in a crowded market
- Success strategies - non-dilutive financing, attracting investors
and partners, flexible business models. Learn from companies that
transformed major challenges into success
|
| When & Where |
November 1st, 14:00 to 18:00
The day before the BIO-Europe Conference in Vienna, Austria
|
| Who should attend? |
This course is targeted to business development professionals
in the anti-infective field, CEOs, alliance management professionals,
and scientists who have interaction with business development. As
networking and discussion is part of the event, you will benefit
from the deep experience of other attendees.
Reserve your seat now as attendance is limited!
|
| Cost |
590€ early bird registration by Sept 30th,
690€ after Sept 30th
|
| Registration |
For more information or to register, please send contact details
to u.theuretzbacher@cefaia.com
|
| Ursula Theuretzbacher Ph.D |
Dr. Theuretzbacher's work to generate research portfolios, discover
and assess licensing opportunities, and develop optimal R&D
strategies in the anti-infective field has been vital to the business
success of numerous start-up and established companies. Dr. Theuretzbacher
offers an integrated approach based on scientific expertise, knowledge
of the anti-infective market, and international presence to help
her clients put in place strategy and tactics to maximize returns
on investment. An internationally sought after speaker and author,
her highly regarded textbooks, scientific articles, and reviews
accepted by leading scientific publications are significant additions
to the anti-infective frontier. As an invited speaker and professional
organization board member, Dr. Theuretzbacher actively participates
at the highest levels of the professional anti-infective communities.
|
| CEFAIA |
The Center for Anti-Infective Agents (CEFAIA) is a private independent
consulting institute that provides high-level support to both start-up
and established pharmaceutical and biotech companies worldwide in
their pursuit of anti-infective drug development and licensing programs.
Founded as a private independent consulting company in 1988 by Dr.
Ursula Theuretzbacher, CEFAIA has extensive experience assisting
companies to establish research portfolios, assess in-licensing
opportunities, and streamline R&D strategy. Based in Vienna,
Austria, CEFAIA has established an international reputation as the
goto specialist for antibiotics and antifungals in science and business.
Our clients include startup, as well as mid-stage and industry leading
pharmaceutical companies in Europe, Canada, and the U.S with a focus
on anti-infective agents.
|
|
|
 |
